How Short Can We Go With DAAs for HCV?

It looks increasingly likely that the course of direct-acting antiviral (DAA) treatment for hepatitis C (HCV) can be shortened from the current standard of 12 weeks—already a remarkable decrease from sometimes year-long, grueling therapies of the pre-DAA days—to as little as eight weeks for some patients, according to new studies presented at the Liver Meeting sponsored by the American Association for the Study of Liver Diseases.